Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Published:2019-04-24 Issue:1 Volume:12 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Wang Dongxu,Lin Jianzhen,Yang Xu,Long Junyu,Bai Yi,Yang Xiaobo,Mao Yilei,Sang Xinting,Seery Samuel,Zhao Haitao^ORCID

Funder

Center for International Security and Cooperation, Stanford University

International Science and Technology Cooperation Projects

CAMS Innovation Fund for Medical Science

Capital Special Research Project for Health Development

Beijing Natural Science Foundation

National Ten-thousand Talent Program and Beijing Science and Technology Cooperation Special Award Subsidy Project

CAMS Initiative for Innovative Medicine

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-019-0730-9.pdf

Reference140 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261.

3. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.

4. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37.

5. Bindea G, Mlecnik B, Angell HK, Galon J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology. 2014;3(1):e27456.

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Successful treatment of PD1-inhibitor induced psoriasiform dermatitis using IL-17 blockade without compromising immunotherapy efficacy;Journal of Oncology Pharmacy Practice;2024-08-07

3. PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications;Journal of Molecular Medicine;2024-06-27

4. An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial;Future Oncology;2024-06-23

5. SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade;Cancer Immunology, Immunotherapy;2024-06-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3